AP3583A - Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine - Google Patents

Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Info

Publication number: AP3583A
Authority: AP; ARIPO
Prior art keywords: phenylsulfanyl; piperazine; dimethyl; phenyl; therapeutic uses
Prior art date: 2010-08-23

Application number

AP2013006768A

Other languages

English (en)

Other versions

AP2013006768A0 (en

Inventor

Marianne Dragheim

Ioana Florea

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-23

Filing date

2011-08-22

Publication date

2016-02-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-22 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2012-03-31 Publication of AP2013006768A0 publication Critical patent/AP2013006768A0/xx

2016-02-09 Application granted granted Critical

2016-02-09 Publication of AP3583A publication Critical patent/AP3583A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AP2013006768A 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine AP3583A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US35788510P	2010-08-23	2010-08-23
DKPA201000739		2010-08-23
PCT/DK2011/050317 WO2012025123A1 (fr)	2010-08-23	2011-08-22	Utilisations thérapeutiques de 1-[2-(2,4-diméthylphénylsulfanyl)phényl]pipérazine

Publications (2)

Publication Number	Publication Date
AP2013006768A0 AP2013006768A0 (en)	2012-03-31
AP3583A true AP3583A (en)	2016-02-09

Family

ID=44532506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2013006768A AP3583A (en)	2010-08-23	2011-08-22	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Country Status (32)

Country	Link
US (5)	US20130184291A1 (fr)
EP (1)	EP2608789B2 (fr)
JP (1)	JP5902169B2 (fr)
KR (1)	KR101816953B1 (fr)
CN (1)	CN103068389A (fr)
AP (1)	AP3583A (fr)
AR (1)	AR082501A1 (fr)
AU (1)	AU2011295465B8 (fr)
BR (2)	BR112013002194A2 (fr)
CA (1)	CA2807062C (fr)
CL (1)	CL2013000492A1 (fr)
CO (1)	CO6680652A2 (fr)
CY (1)	CY1118886T1 (fr)
DK (1)	DK2608789T4 (fr)
ES (1)	ES2625142T5 (fr)
FI (1)	FI2608789T4 (fr)
HR (1)	HRP20170608T4 (fr)
HU (1)	HUE034155T2 (fr)
IL (1)	IL224371A (fr)
LT (1)	LT2608789T (fr)
ME (1)	ME02674B (fr)
MX (1)	MX349724B (fr)
PL (1)	PL2608789T5 (fr)
PT (1)	PT2608789T (fr)
RS (1)	RS55851B2 (fr)
RU (1)	RU2564666C2 (fr)
SG (1)	SG187649A1 (fr)
SI (1)	SI2608789T2 (fr)
SM (1)	SMT201700239T1 (fr)
TW (1)	TW201212918A (fr)
WO (1)	WO2012025123A1 (fr)
ZA (1)	ZA201301385B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA029060B1 (ru)	2014-01-31	2018-02-28	Эгиш Дьёдьсердьяр Зрт.	Способ получения солей вортиоксетина
CN104119298B (zh) *	2014-08-13	2016-08-24	北京蓝贝望生物医药科技股份有限公司	氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) *	2014-08-13	2016-08-17	北京蓝贝望生物医药科技股份有限公司	沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) *	2015-01-30	2017-06-27	上虞京新药业有限公司	沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
US9820984B1 (en)	2016-07-01	2017-11-21	H. Lundbeck A/S	Dosing regimens for fast onset of antidepressant effect
EP3870292A4 (fr)	2018-10-26	2022-11-09	The Research Foundation for The State University of New York	Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007144005A1 (fr) *	2006-06-16	2007-12-21	H. Lundbeck A/S	1-[2-(2, 4-diméthylphénylsulfanyl)-phényl]pipérazine comme composé présentant une activité sur la sérotonine, 5-ht3 et 5-ht1a pour le traitement du déficit cognitif
WO2009062517A1 (fr) *	2007-11-13	2009-05-22	H. Lundbeck A/S	Utilisations thérapeutiques de composés possédant une activité combinée sur sert, 5-ht3 et 5-ht1a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8430581D0 (en) *	1984-12-04	1985-01-09	Ferrosan As	Treatment
ATE138374T1 (de) *	1991-11-18	1996-06-15	Lilly Industries Ltd	Benzo(b)thiophen-2-carboxamide zur behandlung von krankheiten des zentralnervensystems
US20080103179A1 (en) *	2006-10-27	2008-05-01	Tam Peter Y	Combination Therapy
EP1322854A4 (fr)	2000-10-02	2004-08-04	Rohr Inc	Appareil, procede et systeme permettant de reduire le bruit d'une turbine a gaz
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
TW200848411A (en)	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

2011
- 2011-08-17 TW TW100129338A patent/TW201212918A/zh unknown
- 2011-08-19 AR ARP110103029A patent/AR082501A1/es not_active Application Discontinuation
- 2011-08-22 US US13/812,073 patent/US20130184291A1/en not_active Abandoned
- 2011-08-22 FI FIEP11749331.2T patent/FI2608789T4/fi active
- 2011-08-22 RS RS20170404A patent/RS55851B2/sr unknown
- 2011-08-22 KR KR1020137004481A patent/KR101816953B1/ko active Active
- 2011-08-22 HR HRP20170608TT patent/HRP20170608T4/hr unknown
- 2011-08-22 RU RU2013112890/15A patent/RU2564666C2/ru active
- 2011-08-22 SG SG2013007380A patent/SG187649A1/en unknown
- 2011-08-22 PT PT117493312T patent/PT2608789T/pt unknown
- 2011-08-22 DK DK11749331.2T patent/DK2608789T4/da active
- 2011-08-22 SM SM20170239T patent/SMT201700239T1/it unknown
- 2011-08-22 PL PL11749331.2T patent/PL2608789T5/pl unknown
- 2011-08-22 IL IL224371A patent/IL224371A/en active IP Right Grant
- 2011-08-22 ES ES11749331T patent/ES2625142T5/es active Active
- 2011-08-22 ME MEP-2017-94A patent/ME02674B/fr unknown
- 2011-08-22 LT LTEP11749331.2T patent/LT2608789T/lt unknown
- 2011-08-22 WO PCT/DK2011/050317 patent/WO2012025123A1/fr not_active Ceased
- 2011-08-22 JP JP2013525143A patent/JP5902169B2/ja active Active
- 2011-08-22 AP AP2013006768A patent/AP3583A/xx active
- 2011-08-22 BR BR112013002194A patent/BR112013002194A2/pt not_active Application Discontinuation
- 2011-08-22 AU AU2011295465A patent/AU2011295465B8/en active Active
- 2011-08-22 BR BR122020025600A patent/BR122020025600A2/pt not_active Application Discontinuation
- 2011-08-22 SI SI201131177T patent/SI2608789T2/sl unknown
- 2011-08-22 CA CA2807062A patent/CA2807062C/fr active Active
- 2011-08-22 HU HUE11749331A patent/HUE034155T2/en unknown
- 2011-08-22 MX MX2013001570A patent/MX349724B/es active IP Right Grant
- 2011-08-22 EP EP11749331.2A patent/EP2608789B2/fr active Active
- 2011-08-22 CN CN2011800406861A patent/CN103068389A/zh active Pending
2013
- 2013-02-20 CL CL2013000492A patent/CL2013000492A1/es unknown
- 2013-02-21 CO CO13035030A patent/CO6680652A2/es unknown
- 2013-02-22 ZA ZA2013/01385A patent/ZA201301385B/en unknown
2017
- 2017-05-10 CY CY20171100501T patent/CY1118886T1/el unknown
2018
- 2018-09-07 US US16/124,497 patent/US20190000836A1/en not_active Abandoned
2020
- 2020-05-18 US US16/877,108 patent/US20210085674A1/en not_active Abandoned
2022
- 2022-01-07 US US17/570,998 patent/US20220370439A1/en not_active Abandoned
2023
- 2023-10-10 US US18/483,780 patent/US20240293397A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007144005A1 (fr) *	2006-06-16	2007-12-21	H. Lundbeck A/S	1-[2-(2, 4-diméthylphénylsulfanyl)-phényl]pipérazine comme composé présentant une activité sur la sérotonine, 5-ht3 et 5-ht1a pour le traitement du déficit cognitif
WO2009062517A1 (fr) *	2007-11-13	2009-05-22	H. Lundbeck A/S	Utilisations thérapeutiques de composés possédant une activité combinée sur sert, 5-ht3 et 5-ht1a

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTIGAS, F., ET AL, "A Randomised, double-blind, placebo-controlle, active-referenced study of LuAA21004 in patients with major depression". European Neuropsychopharmacology, 2009, vol. 19, pages S426-S427 *

Also Published As

Publication number	Publication date
DK2608789T3 (en)	2017-05-15
KR101816953B1 (ko)	2018-01-09
US20210085674A1 (en)	2021-03-25
MX2013001570A (es)	2013-03-21
EP2608789B1 (fr)	2017-04-12
RU2013112890A (ru)	2014-09-27
EP2608789B2 (fr)	2024-08-21
JP5902169B2 (ja)	2016-04-13
RU2564666C2 (ru)	2015-10-10
CN103068389A (zh)	2013-04-24
US20240293397A1 (en)	2024-09-05
BR112013002194A2 (pt)	2016-05-31
AU2011295465B2 (en)	2014-06-19
ZA201301385B (en)	2014-04-30
RS55851B2 (sr)	2024-11-29
ES2625142T3 (es)	2017-07-18
JP2013536206A (ja)	2013-09-19
LT2608789T (lt)	2017-05-25
KR20130097162A (ko)	2013-09-02
PL2608789T5 (pl)	2025-11-12
ME02674B (fr)	2017-06-20
IL224371A (en)	2016-07-31
PT2608789T (pt)	2017-05-26
CA2807062A1 (fr)	2012-03-01
AU2011295465A1 (en)	2013-02-07
US20190000836A1 (en)	2019-01-03
RS55851B1 (sr)	2017-08-31
TW201212918A (en)	2012-04-01
SMT201700239T1 (it)	2017-07-18
ES2625142T5 (en)	2025-02-10
AU2011295465B8 (en)	2014-07-10
EP2608789A1 (fr)	2013-07-03
US20220370439A1 (en)	2022-11-24
DK2608789T4 (da)	2024-11-04
BR122020025600A2 (pt)	2021-01-05
PL2608789T3 (pl)	2017-09-29
CL2013000492A1 (es)	2013-06-07
AR082501A1 (es)	2012-12-12
US20130184291A1 (en)	2013-07-18
CA2807062C (fr)	2018-07-31
WO2012025123A1 (fr)	2012-03-01
SI2608789T2 (sl)	2025-05-30
CY1118886T1 (el)	2018-01-10
FI2608789T4 (fi)	2024-11-01
HRP20170608T4 (hr)	2024-12-06
HUE034155T2 (en)	2018-01-29
AP2013006768A0 (en)	2012-03-31
SG187649A1 (en)	2013-03-28
SI2608789T1 (sl)	2017-06-30
CO6680652A2 (es)	2013-05-31
HRP20170608T1 (hr)	2017-07-28
MX349724B (es)	2017-08-10

Publication	Publication Date	Title
ZA201105992B (en)	2012-10-31	Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
ZA201107731B (en)	2013-02-27	Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
IL246600B (en)	2018-10-31	Heterocyclic compounds and their use
CO7000771A2 (es)	2014-07-21	Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
PL2521450T3 (pl)	2015-07-31	Grzybobójcze związki heterocykliczne
IL225770A0 (en)	2013-06-27	Heterocyclic compounds
EP2637669A4 (fr)	2014-04-02	Composés hétérocycliques et utilisations de ceux-ci
EP2643000A4 (fr)	2014-05-21	Pipérazines thérapeutiques
ZA201201360B (en)	2013-05-29	New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
EP2656872A4 (fr)	2014-06-04	Coussin d'électrode pour ionophorèse
AP2013006987A0 (en)	2013-07-31	Heterocyclic compounds suitable for the treatment of dyslipidemia
IL223721A0 (en)	2013-03-05	Heterocyclic compounds, their preparation and their therapeutic application
IL213917A0 (en)	2011-11-30	Novel compounds for medical use as peptidase effectors
AP3583A (en)	2016-02-09	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
ZA201205879B (en)	2015-04-29	Piperazines as antimalarial agents
GB201019043D0 (en)	2010-12-22	Use of 2',5'-oligoadenylate derivative compounds
AU2012900131A0 (en)	2012-02-02	"Heterocyclic compounds"
PL393335A1 (pl)	2012-07-02	Nowe E-1,2-bis{4-[(2-(1-oxo-alkilo)-3-oxo-alkilo]fenylo) eteny oraz sposób ich otrzymywania
GB201009514D0 (en)	2010-07-21	Novel heterocyclic compounds
GB201021416D0 (en)	2011-01-26	Novel heterocyclic compounds
GB201101822D0 (en)	2011-03-16	Novel heterocyclic compounds 2
GB201102024D0 (en)	2011-03-23	Novel heterocyclic compounds 3
GB201101823D0 (en)	2011-03-16	Novel heterocyclic compounds 4
GB201101821D0 (en)	2011-03-16	Novel heterocyclic compounds 1
GB201004479D0 (en)	2010-05-05	Therapeutic use of new compounds I